Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

A team led by UCL researchers with Great Ormond Street Hospital (GOSH) and Moorfields Eye Hospital, found B cells—alongside T ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene therapy and pharmaceutical developmentEMERYVILLE ...

UK scientists have explored the role of B cells and T cells in the development of uveitis among patients with juvenile idiopathic arthritis ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

The Charles Street Jail, completed in 1851, housed some of Boston’s most notorious criminals for nearly 150 years. But in 1973, prisoners revolted over poor living conditions, and the jail was ...

The firm said it expects to advance development of cell therapies and radioconjugates for cancer, blood disorders, and autoimmune diseases in China.